Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib for Pediatric Ependymoma (Rollover from OSI-774-205)
NCT01247922Phase 2Terminated
- Sponsor
- OSI Pharmaceuticals
- Start
- May 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of erlotinib in ependymoma, sponsored by OSI Pharmaceuticals. Started May 2011; status: terminated.
02
Drugs
erlotinib
03
Conditions
ependymoma
Beyond the preview
Go deeper on NCT01247922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01247922.